Meeting
2012 ASCO Annual Meeting
Second-line treatment of advanced urothelial cancer with paclitaxel and RAD001 (everolimus) in a German phase II trial (AUO trial AB 35/09).
Authors
Guenter Niegisch
Department of Urology, Heinrich-Heine-University, Duesseldorf, Germany
Guenter Niegisch , Margitta Retz , Mark K. Thalgott , Stefan Balabanov , Friedemann Honecker , Michael Stöckle , Carsten Henning Ohlmann , Martin Boegemann , Frank vom Dorp , Juergen Gschwend , Arndt Hartmann , Christian Ohmann , Peter Albers
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer
Track
Genitourinary Cancer
Sub Track
Bladder Cancer
Clinical Trial Registration Number
NCT00933374
Citation
J Clin Oncol 30, 2012 (suppl; abstr 4590)
DOI
10.1200/jco.2012.30.15_suppl.4590
Abstract #
4590
Poster Bd #
3E
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Hcrn GU15-215: A phase II trial of atezolizumab (atezo) and bevacizumab (bev) in cisplatin-ineligible patients (pts) with advanced/unresectable urothelial cancer (UC).
First Author: Arjun Vasant Balar
Poster
2020 ASCO Virtual Scientific Program
Phase II study of nivolumab and ipilimumab for advanced rare genitourinary cancers.
First Author: Bradley Alexander McGregor
Poster
2019 ASCO Annual Meeting
Dora: A randomized phase II multicenter maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum responsive advanced triple-negative breast cancer (aTNBC).
First Author: Sarah Sammons
Poster
2018 ASCO Annual Meeting
Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC).
First Author: Jacqueline Vuky